Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Data Confirms Safety, Immunogenicity of IFN-K

By Drug Discovery Trends Editor | July 27, 2011

Neovacs published data from a phase 1/2 study with IFN?-Kinoid in Lupus patients who received 240 mcg of IFN-K, the highest dose of IFN-K tested.

The IFN-K-001 Phase 1/2 study is a double-blind, placebo-controlled, dose-escalation design testing four different IFN?-Kinoid dose levels. All patients recruited have mild to moderate lupus. The main endpoints of the trial are the safety and tolerance of the IFN?-Kinoid, its capacity to induce an antibody response to IFN?, the evolution of clinical disease and biomarkers for disease activity, including the interferon signature which measures changes in the activity of genes that are overexpressed in Lupus. Results for the highest dose group of 8 patients at 240 mcg (including 2 placebo patients) are presented and confirm data previously presented with the first three dose groups (30, 60 or 120 mcg of the Kinoid), comprising 20 patients

Results confirm IFN-K is well tolerated and generated a down regulation of overexpressed genes associated with interferon ? and lupus. IFN-K, at the dose of 240 mcg, induced the production of antibodies to interferon ? in all patients. In some patients, the antibodies could be measured as early as day 28, i.e. after the first 2 injections.

IFN-K induced the production of anti-interferon ? antibodies in all patients (instead of 80% of patients as previously observed) in all doses.

Release Date: July 26, 2011
Source: Neovacs 


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE